Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
1023650-66-9
Purity
95%
PF-3882845 is a potent and selective Mineralocorticoid receptor (NR3C2) antagonist for hypertension and nephropathy.
Properties
Name
PF-3882845
Smiles
OC(=O)C=1C=CC=2C3=NN([C@@H](C4CCCC4)[C@H]3CCC2C1)C=5C=CC(C#N)=C(Cl)C5
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
PF-3882845, also referred to as PF-03882845 or PF 03882845, is a selective non-steroidal mineralocorticoid receptor antagonist commonly employed in pharmacological and translational studies. Developed within PF-3882845 Pfizer research programs, the compound is investigated for its effects on aldosterone-mediated signaling mechanisms. Registered under CAS 1023650-66-9, it is particularly relevant to research focused on cardiovascular and renal disorders where high receptor selectivity is required.
Scientists frequently evaluate PF-3882845 chemical structure to better characterize its receptor binding behavior and selectivity characteristics. In addition, PF-3882845 molecular weight is an important parameter during assay preparation and compound validation, supporting accurate dosing and reproducibility across experimental systems.
Application PF-3882845 is primarily focused on studies involving mineralocorticoid receptor signaling and associated disease mechanisms. The compound is used in both early-stage discovery and advanced preclinical models where precise receptor targeting is required.
Its well-characterized profile makes PF-03882845 a reliable reference compound in studies investigating fibrosis, inflammation, and electrolyte regulation pathways.
In vivo, PF-03882845 has been evaluated in preclinical and early clinical settings, demonstrating activity in models of aldosterone-mediated kidney damage. Studies indicate its ability to reduce biomarkers associated with renal stress, supporting its use in translational research. These findings highlight its relevance in dose-response analysis and therapeutic pathway exploration.
The primary mechanism of PF-3882845 involves selective antagonism of the mineralocorticoid receptor, which regulates fluid balance, blood pressure, and tissue remodeling processes. Unlike steroidal compounds, PF-3882845 shows improved selectivity, minimizing off-target interactions with other nuclear receptors.
This specificity allows researchers to isolate MR-driven biological responses, making PF 03882845 valuable for studies focused on receptor signaling, gene expression changes, and downstream physiological effects.
PF-3882845 offers a combination of well-documented activity, selectivity, and experimental relevance, making it suitable for a wide range of research applications. When sourced as EBC-421063, it is supported by quality control standards and analytical validation.
As part of a broader catalog of bioactive molecules, PF-3882845 supports efficient compound selection and integration into research workflows, enabling scientists to advance studies with confidence and precision.
Target name
Target pX
Target action
doi
SDS
PF-03882845 | PF-3882845
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$85
2 mg
$85
5 mg
$150
10 mg
$260
15 mg
$315
20 mg
$370
25 mg
$450
30 mg
$530
35 mg
$610
40 mg
$690
45 mg
$740
50 mg
$789
75 mg
$1049
100 mg
$POA
Quantity
1
Total amount
$ 150
PF-03882845 | PF-3882845
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.